Previous studies have demonstrated that these models recapitulate elements of the tolerogenic tumor microenvironment present in patients, which are mediated to a large degree by immune checkpoint mechanisms, such as the PD-1/PD-L1 axis24,29,30. The gene discussed is PDCD1; the disease is neoplasm.